CVS just did something the market didn't see coming: it hit the numbers, and then it went ahead and raised the bar for the rest of the year. Shares jumped in early trading Wednesday after the company reported second-quarter earnings that blew past Wall Street's expectations. The turnaround story is real.
The headline numbers: adjusted earnings per share of $2.15, crushing the $1.94 analysts had penciled in. Revenue came in at $95.4 billion, a 6% jump from last year. And the company raised its full-year adjusted EPS guidance to a range of $7.50 to $7.70, up from the previous $7.20 to $7.40. That's not a tweak — that's a statement.
The Insurance Unit Is Finally Pulling Its Weight
Let's get straight to the heart of it. Aetna, CVS's insurance arm, has been the anchor dragging down the entire ship for what feels like forever. Medical costs spiked, Medicare Advantage star ratings tanked, and investors were ready to write it off. But this quarter, the medical benefit ratio — the percentage of premiums spent on medical care — came in at 82.4%, better than the 84% Wall Street expected. That's the number that matters, and it's finally heading in the right direction.
The company says the improvement is due to better pricing, tighter utilization management, and — quietly — a ton of work on the Medicare Advantage side. It's not fixed yet, but the trajectory is clear. If Aetna keeps this up, CVS isn't just a pharmacy chain anymore; it's a healthcare powerhouse that happens to sell candy bars.
“This quarter tells me the pieces are coming together. The question is whether they can sustain it.”
CVS also announced a new collaboration with Eli Lilly that will make Zepbound — the blockbuster weight-loss drug — and its sister drug Foundayo accessible to eligible patients right on the CVS Health app. That's a bold move. It puts CVS at the center of the weight-loss revolution, and it's not just about selling drugs. It's about being the one-stop shop for patients who want to manage their health without jumping through hoops.
The Weight-Loss Gold Rush
Everyone's chasing Ozempic and Zepbound these days. But CVS is doing something smarter than just stocking the shelves. The collaboration with Lilly means patients can get the drug prescribed, filled, and delivered all through the app. That's a patient experience play, and it could be a massive loyalty driver.
Here's the catch: these drugs are expensive, and insurance coverage is spotty. CVS and Lilly are positioning this as a way to expand access, but it's also a way to keep patients inside the CVS ecosystem. If you're taking Zepbound, you're likely stopping by CVS more often — for the prescription, for the follow-up, for the snacks. It's a brilliant business move disguised as a healthcare innovation.
Not Everything Is Rosy
Before you start popping champagne, let's look at the cracks. The retail pharmacy segment — the actual stores — saw same-store sales dip slightly. That's a warning sign. The front of the store is still struggling with shrinking margins on prescriptions and intense competition from Amazon and Walmart.
And then there's the pharmacy benefit manager business, Caremark. It's been under fire from regulators and lawmakers who argue PBMs drive up drug prices. CVS is fighting that narrative, but it's a political storm that isn't going away.
Still, the company's overall adjusted operating income rose 8% to $4.8 billion. That's not a fluke. That's a business that's finding its footing.
What's Next? The Transformation Continues
CEO Karen Lynch has been under pressure to prove that the company's massive pivot into healthcare services — the Oak Street Health clinics, the Signify Health home visits, the Aetna integration — was more than a debt-fueled shopping spree. This quarter gives her ammunition. The company is now forecasting adjusted EPS growth of at least 7% for the year, and it's expecting to generate $7 billion in free cash flow.
The bull case is simple: CVS is becoming the front door to American healthcare. You go there for a flu shot, a prescription, a doctor's visit, and now, a weight-loss drug. The bear case is equally clear: healthcare is messy, regulation is tightening, and the retail side is bleeding.
For now, the market is buying the bull case. Shares are up 4% on the day, and the mood in the financial world is cautiously optimistic.
But here's the thing about turnarounds: they're hardest to manage when things start going well. Complacency sets in, costs creep back, and the next quarter becomes the real test.
CVS passed this test. The next one is already on the calendar.
